Autopsy report · NCT02016066

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

“Study terminated due to business decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Janssen Pharmaceutical K.K.

Sponsor type

Industry

Conditions

Healthy

Interventions

CR6261; Placebo

Participants

0

Sites

1

Countries

Japan

Trials that died the same way

• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
  “Study terminated due to business and strategic decision” (95% match in meaning)
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
  “Study terminated for business reasons” (92% match in meaning)
• Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
  “Study terminated due to business priorities” (92% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (91% match in meaning)
• A Study of LY3549492 in Healthy Weight Adult Participants
  “Study terminated for strategic business reasons” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.